Polynovo Ltd

MFJ

Company Profile

  • Business description

    Polynovo earns majority of its revenue from U.S sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.

  • Contact

    320 Lorimer Street
    Unit 2
    Port MelbourneVIC3207
    AUS

    T: +61 386814050

    https://www.polynovo.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    Employees

    301

Stocks News & Analysis

stocks

CBA earnings: Business lending powers on, but costs and credit bear watching

Our view after the bank reports first quarter earnings.
stocks

Apple earnings review: Revenue beats estimates as memory crunch threatens margins

Apple shares are trading at record highs after posting solid results.
stocks

Nvidia: Cutting our fair value estimate by 19% given the firm’s CEO transition and turmoil

We’re reducing our long-term revenue estimates.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,204.5069.70-0.75%
CAC 408,368.917.550.09%
DAX 4026,749.9521.93-0.08%
Dow JONES (US)52,347.5550.460.10%
FTSE 10010,902.5639.470.36%
HKSE23,637.60370.95-1.55%
NASDAQ25,136.27229.82-0.91%
Nikkei 22561,142.35322.990.53%
NZX 50 Index14,173.6885.55-0.60%
S&P 5007,561.6730.73-0.40%
S&P/ASX 2009,082.2064.60-0.71%
SSE Composite Index3,634.3521.48-0.59%

Market Movers